NATCAPSUQ - Natural Capsules
📢 Recent Corporate Announcements
Natural Biogenex, a material subsidiary of Natural Capsules Limited, has entered into a strategic framework agreement with Fermbox Bio to bolster fermentation-based CDMO capabilities. As part of the deal, Fermbox will provide equipment worth up to ₹60 crore at NBPL's Tumkur facility. This collaboration enables the company to target global biopharma and industrial biotech clients using advanced fermentation technology. The partnership is strategically timed to benefit from India's BioE3 Policy and the growing global demand for outsourced biomanufacturing.
- Natural Biogenex (NBPL) signs definitive agreements with Fermbox Bio for fermentation-based CDMO services.
- Fermbox Bio to provide advanced equipment placement and technology worth up to ₹60 crore at NBPL’s Tumkur plant.
- NBPL will handle GMP-compliant manufacturing, quality assurance, and regulatory compliance for the partnership.
- The collaboration targets high-value segments in both pharmaceutical and industrial biotechnology.
- The move aligns with the Indian government's BioE3 Policy to accelerate biomanufacturing innovation.
Natural Biogenex Private Limited (NBPL), a material subsidiary of Natural Capsules Limited, has entered into a Framework and Contract Manufacturing agreement with Fermbox Bio Private Limited. Under this agreement, Fermbox will utilize the spare fermentation capacity of NBPL's plant. Significantly, Fermbox will invest up to ₹60 Crores in plant and machinery that will be owned by them but housed within NBPL's factory. This strategic move allows the company to monetize idle assets and leverage external capital for equipment, likely enhancing the subsidiary's operational throughput and revenue.
- Material subsidiary NBPL enters into a Framework & Contract Manufacturing agreement with Fermbox Bio.
- Fermbox to invest up to ₹60 Crores in specialized plant and machinery at NBPL's facility.
- The agreement aims to utilize the existing spare capacity of NBPL's fermentation plant.
- Investment in machinery is funded by Fermbox while being integrated into NBPL's operational site.
- The transaction is conducted at arm's length and does not involve related party interests.
Natural Capsules Limited has initiated communication with shareholders whose email addresses are not registered with the company or its Registrar & Transfer Agent. The communication provides a direct web link to the Postal Ballot Notice, enabling shareholders to participate in the voting process electronically. The company is also urging these shareholders to update their KYC details and email addresses to streamline future regulatory communications. The eligibility for this postal ballot was determined based on the shareholding records as of February 20, 2026.
- Communication sent to shareholders without registered email addresses as of the February 20, 2026 cut-off date.
- Provides a direct web link to the Postal Ballot Notice on the company's compliance page.
- Urges shareholders to update KYC details for both demat and physical shareholding modes via Cameo Corporate Services Limited.
- Compliance with SEBI Regulation 30 and 36(1)(b) regarding shareholder disclosures and electronic voting.
Natural Capsules Limited has issued a postal ballot notice to seek shareholder approval for increasing the limits of investments, loans, and guarantees under Section 186 of the Companies Act. The company is proposing a new aggregate limit of ₹250 Crore, which would allow the Board greater flexibility in capital deployment and inter-corporate financial support. The approval is being sought through a special resolution via electronic voting. This move suggests the company may be preparing for future expansions, acquisitions, or strategic investments.
- Proposed enhancement of limits for loans, investments, and guarantees to a maximum of ₹250 Crore.
- Approval sought via Special Resolution through a Postal Ballot process conducted electronically.
- E-voting period is scheduled from February 26, 2026, to March 27, 2026.
- The cut-off date for determining shareholder eligibility for voting was February 20, 2026.
Natural Capsules reported a weak Q3 FY26 with consolidated revenue declining 14% Y-o-Y to ₹37.75 Cr, primarily due to a temporary regulatory shutdown of its Puducherry unit. The company posted a net loss of ₹7.12 Cr compared to a marginal profit in the previous year, as EBITDA margins crashed to -6.16% from 9.73% Y-o-Y. While the Puducherry plant has resumed operations and US tariffs on HPMC capsules have eased, the API fermentation block continues to face commercial scale-up challenges. Management is now exploring contractual partnerships to improve asset utilization and expects a recovery in Q4 FY26.
- Consolidated Revenue fell 14% Y-o-Y to ₹37.75 Cr due to regulatory issues and deferred dispatches at the Puducherry facility.
- EBITDA turned negative at -₹2.33 Cr, with margins contracting by 1,589 bps Y-o-Y to -6.16%.
- Net Loss for the quarter stood at ₹7.12 Cr, bringing the 9M FY26 total loss to ₹19.69 Cr.
- US trade tariffs on HPMC capsules have been eased, restoring growth visibility in the North American market.
- Company is in advanced talks with partners for contract manufacturing at its fermentation block to mitigate technical scale-up delays.
Natural Capsules reported a significant decline in financial performance for the quarter ended December 31, 2025. Standalone revenue fell 21% YoY to ₹34.15 crore, while net profit plummeted 79% YoY to just ₹0.36 crore. On a consolidated basis, the company barely broke even with a net profit of ₹0.10 crore. The board also approved the allotment of 45,000 equity shares under its ESOP scheme and is seeking to increase its investment limits via postal ballot.
- Standalone Net Profit declined sharply to ₹36.23 Lakhs from ₹170.32 Lakhs in the previous year's quarter.
- Revenue from operations decreased to ₹3,414.64 Lakhs compared to ₹4,341.18 Lakhs YoY.
- Consolidated Net Profit for Q3 FY26 stood at a marginal ₹10.33 Lakhs, down from ₹250.78 Lakhs in Q2 FY26.
- Paid-up share capital increased to ₹10.38 Crore following the allotment of 45,000 ESOP shares at ₹10 each.
- Board approved a postal ballot to enhance limits for loans and investments under Section 186 of the Companies Act.
Natural Capsules Limited has allotted 45,000 equity shares following the exercise of options under its ESOP 2025 plan, increasing the paid-up capital to Rs 10.39 crore. However, the company's standalone financial results for Q3 FY25 show a significant downturn, with net profit plunging to Rs 36.23 lakhs from Rs 170.32 lakhs in the same quarter last year. Revenue from operations also declined to Rs 3,414.64 lakhs compared to Rs 4,341.18 lakhs YoY. Additionally, the board has approved a postal ballot to enhance limits for inter-corporate loans and investments under Section 186.
- Allotment of 45,000 equity shares at an exercise price of Rs 10 per share under ESOP 2025.
- Standalone Net Profit for Q3 FY25 fell sharply to Rs 36.23 lakhs from Rs 170.32 lakhs YoY.
- Revenue from operations decreased by approximately 21% YoY to Rs 3,414.64 lakhs.
- Total paid-up share capital increased from Rs 10,34,11,540 to Rs 10,38,61,540.
- Board approved seeking shareholder approval to enhance investment and loan limits under Section 186.
Natural Capsules Limited reported a significantly weak performance for Q3 FY25, with revenue from operations dropping 21.3% YoY to ₹34.15 crore. Net profit witnessed a sharp decline of 78.7% YoY, falling to ₹36.23 lakhs from ₹1.70 crore in the year-ago period. On a sequential basis, profits fell nearly 87% from ₹2.81 crore in Q2 FY25. The company also approved the allotment of 45,000 equity shares under its ESOP scheme and is seeking shareholder approval to increase investment and loan limits.
- Revenue from operations declined to ₹3,414.64 lakhs in Q3 FY25 from ₹4,341.18 lakhs in Q3 FY24.
- Net profit for the quarter stood at ₹36.23 lakhs, a massive drop from ₹281.04 lakhs in the preceding quarter.
- Basic EPS fell sharply to ₹0.35 from ₹2.72 in Q2 FY25 and ₹1.65 in Q3 FY24.
- Allotted 45,000 equity shares of ₹10 face value at an exercise price of ₹10 per share under ESOP 2025.
- Board approved a Postal Ballot to enhance limits for loans, guarantees, and investments under Section 186 of the Companies Act.
Natural Capsules Limited reported a significant decline in financial performance for the quarter ended December 31, 2025. Standalone revenue from operations fell 21.3% YoY to ₹34.15 crore, while net profit saw a sharp 78.7% YoY drop to ₹0.36 crore. On a sequential basis, the profit decline was even steeper, falling 87% from ₹2.81 crore in Q2 FY26. The board also approved the allotment of 45,000 ESOP shares and is seeking to enhance investment limits under Section 186 of the Companies Act.
- Standalone Revenue from operations declined 21.3% YoY to ₹3,414.64 Lakhs from ₹4,341.18 Lakhs.
- Net Profit crashed 78.7% YoY to ₹36.23 Lakhs compared to ₹170.32 Lakhs in the previous year's quarter.
- Total expenses for the quarter stood at ₹3,579.48 Lakhs, leading to a significant compression in margins.
- Allotted 45,000 equity shares of ₹10 each under the ESOP 2025 plan, increasing paid-up capital to ₹10.38 crore.
- Board approved a Postal Ballot to increase limits for loans and investments under Section 186 of the Companies Act.
Natural Capsules Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing, covering the quarter ended December 31, 2025, confirms that the company and its Registrar, Cameo Corporate Services Limited, have processed all dematerialization requests within the mandated timeframes. This process involves the mutilation and cancellation of physical share certificates and updating the depository as the registered owner. Such filings are standard administrative requirements for listed companies in India to ensure the integrity of electronic shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Registrar Cameo Corporate Services Limited confirmed all dematerialization requests were accepted or rejected as per norms.
- Physical share certificates were mutilated and cancelled after due verification by the depository participant.
- The name of the depository has been substituted in the register of members as the registered owner within stipulated limits.
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited, has decided to cancel its planned Rights Issue. The decision was finalized during a board meeting on January 03, 2026, following the non-subscription of shares by the major shareholder. This Rights Issue was previously announced on September 30, 2025, and its cancellation indicates a setback in the subsidiary's capital raising efforts. Investors should note that this could impact the subsidiary's planned projects or debt management.
- Material subsidiary Natural Biogenex Private Limited cancels Rights Issue allotment.
- Cancellation is attributed to non-subscription by the major shareholder.
- The Rights Issue was originally initiated following an intimation on September 30, 2025.
- Board decision to halt the process was made on January 03, 2026.
Natural Capsules Limited has been directed by the Department of Drug Controller to temporarily cease operations at its Pondicherry manufacturing plant as of December 26, 2025. The regulatory action was triggered by the company supplying material to a customer whose drug license had expired. While the company has initiated corrective actions and is seeking revocation of the order, the immediate halt in production poses an operational risk. The management is currently assessing the specific financial impact resulting from this shutdown.
- Department of Drug Controller ordered temporary closure of the Pondicherry plant on December 26, 2025
- The regulatory violation involved supplying materials to a client with an expired drug license
- Company has initiated corrective measures and is preparing documents for revocation of the order
- Total financial impact of the operational halt is yet to be quantified by the management
Natural Capsules Limited has notified the exchanges that its trading window for dealing in equity shares will be closed starting January 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results is yet to be announced.
- Trading window closure effective from January 1, 2026
- Closure is related to the financial results for the quarter ending December 31, 2025
- Window to reopen 48 hours after the official declaration of financial results
- Applies to all Designated Persons and their immediate relatives as per SEBI norms
Financial Performance
Revenue Growth by Segment
The capsule business remains the primary revenue driver, growing 11.11% YoY to Rs. 45.80 Cr in Q2 FY26. The API segment is in a nascent stage, contributing only Rs. 1.22 Cr in revenue for the same quarter. Overall H1 FY26 revenue reached Rs. 91.01 Cr, a 13.18% increase from Rs. 80.41 Cr in H1 FY25.
Geographic Revenue Split
Not disclosed in available documents; however, the company is focusing on increasing exports to regulated markets and international marquee pharma clients to enhance margins and stabilize the topline.
Profitability Margins
Profitability has been severely impacted by the API segment's slow ramp-up. The company reported a net loss of Rs. 6.99 Cr in Q2 FY26 compared to a loss of Rs. 0.61 Cr in Q2 FY25. H1 FY26 net loss widened to Rs. 12.57 Cr from a marginal loss of Rs. 0.01 Cr in H1 FY25.
EBITDA Margin
Consolidated EBITDA margin for Q2 FY26 was negative 1.93%, a sharp decline of 1286 bps from 10.93% in Q2 FY25. This was driven by an operating loss of Rs. 11.47 Cr in the API division, while the capsule division maintained margins between 11.5% and 12%.
Capital Expenditure
The company is incurring incremental capex of Rs. 10-12 Cr in its subsidiary, Natural Biogenex Private Limited (NBPL), for a Phase-2 fermenter in FY26. This follows significant historical investment in the steroidal API facility and HPMC capsule lines.
Credit Rating & Borrowing
ICRA downgraded NCL's ratings due to a weakened financial profile and slow API ramp-up. Total debt to operating profit deteriorated to 6.4 times as of March 31, 2025, compared to 2.8 times on March 31, 2023. The company has a consolidated debt repayment obligation of Rs. 10.5 Cr in FY26.
Operational Drivers
Raw Materials
Primary raw materials include Gelatin and HPMC (Hydroxypropyl Methylcellulose). Specific percentage of total cost for each is not disclosed, but pricing pressure in gelatin has significantly compressed margins.
Capacity Expansion
NCL has a current capsule capacity of 20 billion units. It is expanding its HPMC capacity with three new lines; one became operational in Q4 FY24, and the remaining two are expected by Q4 FY25. The API facility is also scaling up commercial production.
Raw Material Costs
Raw material costs are rising as a percentage of revenue due to pricing pressure in the gelatin capsules business, where realizations declined in FY24 and H1 FY25, leading to OPM falling from 19.9% in FY23 to 12.2% in FY24.
Manufacturing Efficiency
The API division requires a capacity utilization of 25-30% (approximately Rs. 100 Cr revenue) to achieve a cash break-even. Current utilization is significantly lower, contributing to quarterly losses of ~Rs. 10 Cr.
Strategic Growth
Expected Growth Rate
23-25%
Growth Strategy
Growth will be achieved by transitioning from low-end domestic customers to high-value international pharma clients, leveraging PLI scheme incentives for steroidal APIs, and operationalizing new HPMC capsule lines which command higher margins (16-18%).
Products & Services
Hard Gelatin Capsules, HPMC (Vegetarian) Capsules, and Steroidal Active Pharmaceutical Ingredients (APIs).
Brand Portfolio
Natural Capsules Limited (NCL), Natural Biogenex Private Limited (NBPL).
New Products/Services
New steroidal APIs and expanded HPMC capsule variants are expected to be the primary contributors to the targeted Rs. 225 Cr topline for FY26.
Market Expansion
Focusing on regulated markets and marquee pharma clients globally to reduce margin volatility and increase the share of high-value exports.
Market Share & Ranking
NCL holds a 20 billion unit capacity, which is approximately 10% of the 200 billion unit Indian capsule market.
Strategic Alliances
The company has a shareholding agreement with Somerset Indus Healthcare Fund II & Somerset Indus Healthcare India Fund.
External Factors
Industry Trends
The industry is shifting toward vegetarian HPMC capsules and domestic API manufacturing. NCL is positioning itself as a dominant player in the domestic steroidal API market to capitalize on the PLI scheme and a 1.3 trillion unit global capsule market.
Competitive Landscape
NCL competes in a fragmented global market of 1.3 trillion capsules, facing pressure from both large-scale global manufacturers and domestic pricing competition in the gelatin segment.
Competitive Moat
The moat is built on technical capabilities in HPMC manufacturing and complex steroidal API processes. These are sustainable due to high regulatory hurdles and the R&D intensity required to scale from lab to commercial production.
Macro Economic Sensitivity
Highly sensitive to global trade policies and tariffs, which directly impacted the company's ability to meet its original FY26 revenue guidance of Rs. 270-280 Cr.
Consumer Behavior
There is an increasing global consumer preference for vegetarian (HPMC) capsules over traditional gelatin-based products, driving NCL's capacity shift.
Geopolitical Risks
Tariffs and shifting regulatory environments in international geographies continue to shape trade flows and business momentum for the capsule export business.
Regulatory & Governance
Industry Regulations
Operations are governed by the PLI scheme for APIs, Pollution Control Board norms, and manufacturing standards required for regulated pharma markets.
Environmental Compliance
The API facility obtained Consent for Operation (CFO) from the Karnataka State Pollution Control Board on January 13, 2025. Specific ESG costs are not disclosed.
Legal Contingencies
The company reports no pending litigations that would impact its financial position other than items disclosed under Note No. 45; the specific value of these items is not disclosed.
Risk Analysis
Key Uncertainties
The primary risk is the slow ramp-up of the API facility (NBPL), which currently generates a quarterly loss of ~Rs. 11.47 Cr. Technical hurdles in scaling production could impact FY26 revenue by up to 17% relative to original guidance.
Geographic Concentration Risk
Not disclosed, though there is a stated intent to shift more volume toward international exports.
Technology Obsolescence Risk
Risks associated with the scale-up of advanced chemical processes from lab to commercial levels; failure to resolve these could lead to sustained cash losses.